The QualityStocks Daily Thursday, February 29th, 2024

Today's Top 3 Investment Newsletters

QualityStocks(ENVB) $1.4500 +74.49%

MarketClub Analysis(SIDU) $8.9800 +61.22%

NetworkNewsWire(IDEX) $1.5800 +54.90%

The QualityStocks Daily Stock List

Enveric Biosciences (ENVB)

MarketClub Analysis, QualityStocks, INO Market Report, StocksEarning, MarketBeat, StockStreetWire, Small Cap Firm, Schaeffer's, Fierce Analyst, StockWireNews, Smartmoneytrading and 247 Market News reported earlier on Enveric Biosciences (ENVB), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Enveric Biosciences Inc. (NASDAQ: ENVB) (FRA: SLZ) is a patient-focused biotech firm specialized in enhancing the lives of patients who have suffered the adverse effects of undergoing conventional cancer treatment. The firm has a goal of testing different natural compounds, especially cannabinoids, in order to develop novel medicinal formulations that clinicians can prescribe to patients exhibiting symptoms of adverse effects of cancer treatment.

The company, which was founded in 1994 and is headquartered in Naples, Florida relies on its extensive global network of oncologists and scientists to leverage the innovative clinical developments within the cannabinoids space to identify opportunities to come up with cannabinoid-based formulations.

Enveric Biosciences has a pipeline of different products which are in varying stages of development. For example, its cannabinoid-based formulation for glioblastoma multiforme is in preclinical development, and so is its candidate for radiation dermatitis. Another candidate targeting chemotherapy-triggered peripheral neuropathy is still in the discovery phase.

Enveric Biosciences (ENVB), closed Thursday's trading session at $1.45, up 74.4886%, on 176,922,601 volume. The average volume for the last 3 months is 9.395M and the stock's 52-week low/high is $0.649/$6.98.

Remark Holdings (MARK)

StockMarketWatch, StreetInsider, MarketClub Analysis, QualityStocks, InvestorPlace, Schaeffer's, MarketBeat, TradersPro, TraderPower, Wall Street Resources, INO.com Market Report, Trades Of The Day, BUYINS.NET, Early Bird, PoliticsAndMyPortfolio, Trading Concepts, SmarTrend Newsletters, Wallstreetlivechat, Marketbeat.com, Fierce Analyst, PennyStocks24, Promotion Stock Secrets, Barchart, Small Cap Firm, StockWireNews, The Online Investor, Timothy Sykes, TopPennyStockMovers, Wall Street Mover and Short Term Wealth reported earlier on Remark Holdings (MARK), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Remark Holdings Inc. (NASDAQ: MARK) (FRA: 3SWN) is a global digital media firm that is focused on developing and deploying artificial intelligence products and artificial-intelligence-based solutions for software developers and other businesses in various industries.

The firm operates as a holding company and is a part of the wired telecommunications services industry. Remark Holdings Inc., which is based in Las Vegas, Nevada, was incorporated on March 14, 2006.

Remark Holdings Inc. owns a subsidiary called Remark Media which operates various digital brands such as FileLater.com, IRS.com, Banks.com and Vegas.com. The firm also owns a unique AI Based Machine Learning Data Intelligence Platform known as KanKan under which it sells its AI-based services and products in the People’s Republic of China. It sells its products and services in the U.S. under the Remark AI brand.

Remark Holdings Inc. also operates different digital media properties that deliver content in various verticals including entertainment and travel, such as show tickets, air travel, lodging and tour through its website. The firm also sells advertising services through its websites as well as financial-technology services and products. This is in addition to publishing Bikini.com, which offers informative and sophisticated content, e-commerce and social media for the beach lifestyle.

Remark Holdings Inc. was recently named as the exclusive marketing partner for an innovative online daily fantasy sports platform. The DFS market has enormous potential and given that it is fast-growing, it will help transform SuperDraft Inc. into the premier DFS company and in turn, allow Remark Holdings to expand its addressable market.

Remark Holdings (MARK), closed Thursday's trading session at $0.3699, up 68.1364%, on 4,221,672 volume. The average volume for the last 3 months is 2.636M and the stock's 52-week low/high is $0.141/$1.83.

Adial Pharmaceuticals (ADIL)

MarketClub Analysis, StockMarketWatch, QualityStocks, BUYINS.NET, TopPennyStockMovers, MarketBeat, TradersPro, The Online Investor, StreetInsider, Small Cap Firm, Schaeffer's, PoliticsAndMyPortfolio, PennyStockScholar, PennyStockProphet and 360wallstreet reported earlier on Adial Pharmaceuticals (ADIL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Adial Pharmaceuticals Inc. (NASDAQ: ADIL) is a clinical-stage biopharmaceutical firm that is engaged in developing treatments for preventing or treating addiction and associated disorders.

The firm has its headquarters in Charlottesville, Virginia and was incorporated in November 2010 by Bankole A. Johnson. It operates as part of the pharmaceutical manufacturing industry, under the healthcare sector, in the biotech and pharma sub-industry and serves consumers in Virginia.

The enterprise’s pipeline is made of a selective serotonin-3 antagonist dubbed AD04, which is indicated for treating alcohol use disorder. The active ingredient in the formulation, i.e. ondansetron, is the serotonin-3 antagonist. The formulation has also been indicated for the treatment of other addictive disorders including smoking, obesity and opioid use disorder, among other drug addictions. The candidate recently concluded its phase 2b study which tested its effectiveness in treating alcohol use disorders, and it demonstrated promising results in decreasing the quantity and frequency of heavy drinking and drinking in general, with no noticeable safety concerns. The enterprise also develops AD01, which is indicated for treating addictive behaviors, and recently concluded phase 1 trials. In addition to this, the enterprise is also involved in the development of drug candidates for non-opioid pain alleviation and other disorders and ailments.

The firm is planning to venture into the genetic testing market after receiving a patent for its AD04 candidate, bringing the firm one step closer to helping identify patients that could benefit from their formulation. This move will also allow the firm to commercialize a companion diagnostic test to AD04 in the future, which will help extend its consumer reach and in turn, bring in even more investors.

Adial Pharmaceuticals (ADIL), closed Thursday's trading session at $2.04, up 25.9259%, on 28,836,043 volume. The average volume for the last 3 months is 1.678M and the stock's 52-week low/high is $0.765/$15.00.

View Inc. (VIEW)

QualityStocks and Zacks reported earlier on View Inc. (VIEW), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

View Inc. (NASDAQ: VIEW) is a technology firm that is engaged in the development, manufacture and sale of smart building products.

The firm has its headquarters in Milpitas, California. Prior to its name change, the firm was known as CF Finance Acquisition Corp II. It operates as part of the glass and glass product manufacturing industry. The firm has five companies in its corporate family and serves consumers across the globe, mainly in the United States.

The company’s objective is to make human environments better by optimizing and increasing the amount of natural light in buildings and decreasing glare and heat. It believes strongly in the positive effect natural light has on productivity, wellness and human health, as well as the benefits of natural light, which is why it manufactures smart building products that enhance people’s experience, productivity and health, while also reducing energy consumption.

The enterprise’s products include an intrusion detection solution dubbed View Smart Protect, which improves the security of a building by detecting glass breakage; View Sense modules which optimize and measure noise, air quality, temperature, humidity and light; Immersive experiences, which transforms smart glass windows into interactive digital and transparent surfaces; a cloud-connected network infrastructure known as View Net; and the View Smart Glass which consists of electrochromic glass panels that are incorporated into glass units.

The firm is focused on strengthening its platforms and broadening its portfolio by investing in research and development, with the aim being to deliver new products to consumers. This will bring in additional revenue and also encourage more investments into the firm, which may have a positive effect on the firm’s growth.

View Inc. (VIEW), closed Thursday's trading session at $1.63, up 24.4275%, on 822,552 volume. The average volume for the last 3 months is 14,871 and the stock's 52-week low/high is $0.6209/$44.046.

Aprea Therapeutics (APRE)

MyBestStockAlerts, MarketClub Analysis, PennyStocks24, MarketBeat, Actual Gains, The Stock Psycho, Top Gun, QualityStocks, Stock Roach, Hot Stock Profits, Mina Mar Marketing Group, PennyPickAlerts, Honest Abe, Trades Of The Day, Penny Picks, Penny Stock Newsletter, Penny Stocks Finder, InvestorSoup, PennyStockRumors.net, OtcShortReport, Fortune Stock Alerts, Fast Moving Stocks, Damn Good Penny Picks, Stock Preacher, BUYINS.NET, Beacon Equity Research, Greenbackers, FreeRealTime, FeedBlitz, Club Penny Stocks Network, Center Stage Stocks, HotStockProfits, Market Wrap Daily, MarketWireStocks, MicroStockProfit, OTC Stock Review, PennyStockProfessor, Pennystocktweeters.com, PREPUMP STOCKS, Real Pennies, RockingPennyStocks, Stock Legends, StockHideout, Stocktamer, TooNiceStocks, TopPennyStockMovers and Orbit Stocks reported earlier on Aprea Therapeutics (APRE), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Aprea Therapeutics Inc. (NASDAQ: APRE) is a biopharmaceutical firm that is focused on the development and commercialization of cancer therapies that reactivate the mutant p53 tumor suppressor protein.

The firm has its headquarters in Boston, Massachusetts and was incorporated in 2006. It operates as part of the healthcare sector, in the biotech and pharma sub-industry and serves consumers in Sweden and the U.S.

The company’s primary shareholders include KCIF Co-Investment Fund KB, Rosetta Capital Ltd. and an investment vehicle owned by Karolinska Development AB called KDev Investments AB.

The enterprise’s p53 tumor suppressor protein responds to different forms of cellular stress and activates the transcription of genes which cause apoptosis or cell cycle arrest. Its product portfolio comprises of a p53 reactivator dubbed APR-548, which is undergoing a phase 1 dose-escalation trial for oral administration in patients suffering from myelodysplastic syndromes; and a p53 small molecule reactivator dubbed Eprenetapopt (APR-246), which is currently in late-stage clinical development for various hematologic malignancies as well as other indications. They include acute myeloid leukemia and myelodysplastic syndromes, as well as refractory/relapsed TP53 mutant chronic lymphoid leukemia, non-small cell lung cancer, bladder cancer and gastric cancer. In addition to this, the enterprise is also involved in the development of APR-017, which causes p53-mediated apoptosis by restoring p53 activity in mutant p53 cancer cell lines.

The company recently announced positive results from its trial which evaluated eprenetapopt with azacitidine in the treatment of patients with TP53 mutant acute myeloid leukemia and myelodysplastic syndromes. The success of this new treatment will not only improve patient outcomes for these diseases, which currently have limited treatment options, but also boost investments into the firm, which will have a positive impact on the company’s growth.

Aprea Therapeutics (APRE), closed Thursday's trading session at $8.46, up 17.5%, on 14,961 volume. The average volume for the last 3 months is 153,116 and the stock's 52-week low/high is $2.78/$7.71.

Streamline Health Solutions, Inc. (STRM)

Wall Street Resources, StreetInsider, SmarTrend Newsletters, QualityStocks, Marketbeat.com, TradersPro, StockEarnings, Trading Concepts, TraderPower, Penny Detectives, MarketBeat, Zacks, HotOTC, MarketClub Analysis, CoolPennyStocks, BUYINS.NET, DrStockPick, MicroCap Press, MicrocapVoice, Barchart, SmallCapVoice, Stock Rich, StockEgg, Stockpalooza, Street Insider and Penny Invest reported earlier on Streamline Health Solutions, Inc. (STRM), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Streamline Health Solutions, Inc. is a leader in pre-bill revenue integrity solutions for healthcare providers. Pre-Bill Revenue Integrity as a Service combines automated pre-bill analysis with revenue integrity expertise. The Company’s eValuator™ Revenue Integrity Program identifies and addresses coding and charge accuracy issues before billing. This is to prevent revenue leakage, denials, and also compliance exposure. Streamline Health Solutions is based in Alpharetta, Georgia. The Company lists on the Nasdaq Capital Market.

Streamline Health has technology and services exclusively focused on the middle of the revenue cycle. Through bundling its cloud-based solutions and technology-enabled services in flexible packages, Streamline Health enables providers to select the best combination of technology and support to drive pre-bill revenue integrity and improve financial performance across their organizations.

The eValuator Revenue Integrity Program includes integrated solutions, technology-enabled services, and analytics that drive compliant revenue across the enterprise. Streamline Health eValuator™ is a cloud-based platform. It provides 100 percent automated analysis of inpatient coding and charge accuracy before billing.

Streamline Health eValuator™ analyzes and ranks each case in real time based on the likelihood of accuracy and the estimated impact of recommended corrections. It is backed by automated workflows, strong reporting, as well as market-leading expertise.

Streamline Health Solutions, Inc. (STRM), closed Thursday's trading session at $0.5, up 16.198%, on 264,684 volume. The average volume for the last 3 months is 80,256 and the stock's 52-week low/high is $0.213/$2.08.

Liberty Defense (LDDFF)

We reported earlier on Liberty Defense (LDDFF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Liberty Defense Holdings Ltd (OTCQB: LDDFF) (CVE: SCAN) (FRA: LD2A) is a company focused on developing and commercializing active 3D imaging technology systems for the security industry in the United States and Canada.

The firm has its headquarters in Wilmington, Massachusetts and was incorporated in 2012, on June 8th. It operates as part of the security and protection services industry, under the industrials sector. The firm serves consumers mainly in the U.S. and Canada.

The company is committed towards protecting communities and preserving peace of mind through next-generation security detection solutions. It provides multi-technology security solutions for concealed weapons and threat detection in high-volume foot traffic areas and locations requiring enhanced walk-through security such as airports, stadiums, and schools.

The enterprise’s offerings include its HEXWAVE product, licensed from the Massachusetts Institute of Technology. This product holds patents related to active 3D radar imaging technology and provides layered, stand-off detection capability of metallic and non-metallic weapons. It has also licensed the millimeter wave-based, High-Definition Advanced Imaging Technology body scanner and shoe scanner technologies as part of its technology portfolio. It serves schools, hospitals, theaters, places of worship, hotels, entertainment venues, shopping malls, airports, sports venues, government offices, rails/subways, passengers, and open air events.

The firm’s HEXWAVE system is set to undergo operational test and evaluation at the Port of Oakland at the International Airport facilities, which include the Oakland International Airport and the Oakland Seaport. This partnership will not only enhance security operations at the facilities but also open the firm up to new growth and investment opportunities that may positively influence shareholder value.

Liberty Defense (LDDFF), closed Thursday's trading session at $0.0962, up 1.9068%, on 69,883 volume. The average volume for the last 3 months is 1.71M and the stock's 52-week low/high is $0.0719/$0.2412.

Momo Inc. (MOMO)

StocksEarning, MarketClub Analysis, InvestorPlace, Schaeffer's, StockEarnings, Marketbeat, Market Intelligence Center Alert, Zacks, The Street, Kiplinger Today, Trades Of The Day, Daily Trade Alert, StreetInsider, QualityStocks, The Street Report, Marketbeat.com, BUYINS.NET, The Online Investor, INO.com Market Report, Louis Navellier, TradersPro, TopStockAnalysts, Wealth Insider Alert, StreetAuthority Daily, Trading Concepts, TipRanks, Daily Wealth, Money Morning, Investopedia, FreeRealTime, StockMarketWatch, Greenbackers, StocksImpossible, Street Insider, PennyDoctor, First Penny Picks, CrashTrade, DividendStocks, Barchart, OTCBB Journal, ChartAdvisor, Early Bird, Investing Signal, InvestmentHouse, Jason Bond, AskSlapper, Orbit Stocks, Profit Confidential, Promotion Stock Secrets, Short Term Wealth, Terry's Tips, The Best Newsletters, The Stock Dork and One Hot Stock reported earlier on Momo Inc. (MOMO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

A recent report from Chinese social-media-management platform KAWO has revealed that multinationals in China overwhelmingly use social media as a marketing tool. After surveying 50 international business-to-business multinational corporations (MNCs) in the country, KAWO found that social media is a top marketing tool for MNCs in 20 different sectors.

According to the B2B Social Media Marketing Research Report, 94% of international business-to-business MNCs based in China pointed to social media as a major channel for marketing. In addition, 70% said they plan to increase their social media marketing budgets this year. Furthermore, 86% and 66% of the respondents identified offline events and paid search as top marketing channels with 38% noting that they would increase their paid search marketing budget in 2024. The report noted that the 44% of the respondents also suggested plans to cut their display ad budget.

The survey showed 42% of the polled international B2B MNCs noted that boosting brand awareness was the primary goal when they used social media for B2B marketing while 34% said they utilized it to generate leads. KAWO’s report also states that 88% of the companies used impressions, views and reads as social media metrics, and 80% considered generated leads as social media metrics.

Interestingly, only 18% of international MNCs said they use sales revenue as a social media metric. Although many firms leverage social media marketing to turn leads into potential return sales, tracing a customer’s journey and attributing certain sales to social media is nigh impossible without an efficient revenue contribution model.

KAWO’s chief executive officer Alex Li explains that with more international B2B MNCs looking to break into the Chinese market or expand their operations in the country, navigating China’s unique social media space will undoubtedly be challenging. The social media management platform’s report shows that plenty of marketers will need resources and help to align their social media efforts with corporate objectives and goals, Li said. He adds that companies such as KAWO can help marketers at international B2B MNCs streamline their collaboration efforts, improve efficiencies and make data-informed decisions.

The majority of the respondents (90%) reportedly spend one to three hours every week syncing and reporting with their overseas partners, and 88% noted they would collaborate more effectively with international colleagues if they had a bilingual social media management platform.

Unsurprisingly, WeChat was the top social-media company in China by a wide margin. In fact, 100% of the businesses involved in the poll had WeChat official accounts and 76% of the businesses were on WeChat channels. Overall, 80% of the polled businesses said they believe WeChat is the best platform for achieving their business objectives and goals within the next three years.

This report shows how influential various social media apps such as Momo Inc. (NASDAQ: MOMO) are, not just in China but around the world.

Momo Inc. (MOMO), closed Thursday's trading session at $6.59, off by 2.0802%, on 1,706,564 volume. The average volume for the last 3 months is 730,715 and the stock's 52-week low/high is $5.745/$11.12.

Compass Pathways PLC. (CMPS)

InvestorBrandNetwork, QualityStocks, InvestorPlace, MarketBeat, Daily Trade Alert, Top Pros' Top Picks, StreetInsider, Schaeffer's, Trades Of The Day, The Street, PsychedelicNewsWire and Prism MarketView reported earlier on Compass Pathways PLC. (CMPS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

DMT is a potent psychedelic that has shown potential in reducing depression symptoms. This naturally occurring substance can be found in different animals and plants. When inhaled or ingested, this substance produces intense auditory and visual hallucinations.

Unlike other psychedelics such a psilocybin or LSD, which produce prolonged experiences, DMT’s effects are brief, which make it a more flexible and manageable therapeutic option. A new study examined the therapeutic potential of DMT and its effects on the psychological well-being of individuals.

The study used data from a pair of complementary studies that involved 30 healthy volunteers who had previously used psychedelics. This previous exposure was an important criterion for inclusion, because it helped ensure participants were familiar with the drugs and still felt safe in an altered state of consciousness.

Prior to DMT’s administration, every participant was assessed through psychiatric interviews, medical exams and physical tests to eliminate any possible risk factors. The study involved a prospective sample analysis and placebo, with 13 participants receiving a dose of DMT, which was followed by a placebo a week later. This enabled the investigators to detect any changes that could be attributed to DMT by comparing the results of both sessions.

In the prospective sample, the researchers were focused on determining the impact DMT had on psychological well-being. The investigators observed considerable improvements in symptoms of depression after DMT was administered. This, they explained, highlighted the drug’s potential as a rapid-acting agent.

They also observed a link between the intensity of the feeling of oneness with the world brought on by DMT and improvements in mental-health outcomes. This, they noted, suggested that the psychedelic experience’s qualitative aspects could play a significant role in its therapeutic potential.

In the report, Dr. Chris Timmermann, the author of the study,  stated that DMT had lower scores of symptoms of depression in healthy volunteers in a similar way to LSD and psilocybin. Timmerman is the head of DMT Research Group at Imperial College London’s Centre for Psychedelic Research. Additionally, the investigators observed a considerable drop in neuroticism in the placebo-controlled trial, which suggests that DMT could have a lasting impact on personality traits linked to mental health conditions.

Despite these promising results, the investigators noted that the focus on healthy volunteers with prior psychedelic experience, DMT dosage variability and the methodological differences between the two parts of the research could limit the generalizability of the study’s results.

The researchers are now focused on better understanding the extent to which DMT can safely be administered for therapeutic purposes. Other entities such as Compass Pathways PLC. (NASDAQ: CMPS) are also making headway in studying different psychedelic compounds including psilocybin with the intent to develop therapeutic formulations from them.

Compass Pathways PLC. (CMPS), closed Thursday's trading session at $10.27, off by 16.9766%, on 2,050,381 volume. The average volume for the last 3 months is 977,205 and the stock's 52-week low/high is $5.01/$12.75.

Cresco Labs Inc. (CRLBF)

InvestorPlace, QualityStocks, Kiplinger Today, Daily Trade Alert, MarketBeat, Cabot Wealth, Top Pros' Top Picks, The Street, The Wealth Report, The Online Investor, Wealth Insider Alert, Trading For Keeps, Trades Of The Day, Early Bird, StreetInsider, wyatt research newsletter, TradersPro and StocksEarning reported earlier on Cresco Labs Inc. (CRLBF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Last week, Senate File 32 completed its third reading in the Wyoming senate. The bill has now been forwarded to the state’s House of Representatives. From there, it will be forwarded to undergo committee review and then be debated on the floor. If no amendments are proposed, it will be advanced to the governor’s desk for his veto or approval.

This bill seeks to impose a limitation on psychoactive substances and would eliminate the ability of anyone to sell hemp products that contained HHCo, delta-10, delta-8 and other products with low THC content in the state. This puts independently owned hemp businesses at risk for closure and may also reduce access to this medicinal plant for many who rely on it.

Platte Hemp Company LLC owners, Alicia and Sam Watt, voiced their concerns about how the measure would affect their business. The Watts launched their hemp shop in December 2018, with their primary objective being to offer green alternatives to prescription drugs including opioids and cigarettes.

Sam, an Air Force veteran, also revealed that he used natural alternatives to manage his post-traumatic stress disorder. This, he said, was after the Veterans Administration (“VA”) prescribed narcotics to manage the condition, which only worsened when he mixed the drugs with alcohol.

During a recent interview, the Watts revealed that all their products were tested in a facility in California, adding that nothing was put on their website or shelves without clearance. They also highlighted that there was much to be learned about marijuana, but the Wyoming Association of Sheriffs and Chiefs of Police refused to become educated and change their stance on marijuana.

Last year, a representative from the association gave a presentation on the impact cannabis had had on communities during a city council meeting in Rock Springs.

The Watts also revealed that since 2018, their business had paid more than $550,000 in sales tax revenue. They argued that the senators weren’t seeing the bigger picture because this move wouldn’t help the state’s tax revenue.

Hemp was legalized in 2019 through a farm bill. This measure permits the purchase, possession, use and transportation of hemp and hemp products by any individual without restriction. The bill does note that the level of THC in these products should not exceed 0.3%.

Based on this house bill, the state of Wyoming shouldn’t be able to do this, as a billion-dollar operations will be destroyed in the process if Senate File 32 is approved.

The concerns being raised in Wyoming about synthetic cannabinoids mirror the issues that other jurisdictions like those in which cannabis companies such as Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) currently operate.

Cresco Labs Inc. (CRLBF), closed Thursday's trading session at $1.73, off by 2.2599%, on 736,680 volume. The average volume for the last 3 months is 76.656M and the stock's 52-week low/high is $1.00/$2.77.

HUMBL Inc. (HMBL)

QualityStocks, Trades Of The Day and InvestorPlace reported earlier on HUMBL Inc. (HMBL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

HUMBL (OTC: HMBL) and Avrio today announced the acquisition of the HUMBL Financial brand, products and services by Avrio. Avrio is the parent of several companies delivering licensed digital financial market infrastructure and services across public, private and digital markets. Arkonis, Avrio’s ATS technology, is designed to be used by the operators of private markets that facilitate the issuance and secondary trading of securities and includes a Quotation Bureau, a Transfer Agent, and a Qualified Matching Engine for LP investors. Partnering with Avrio provides HUMBL Financial with the global market access needed to efficiently execute its strategies and scale rapidly in a competitive and complex market environment across stocks, options, crypto, commodities and digital assets, as well as traditional financial products and services that customers would expect inside digital wallets and web platforms. “We believe HUMBL Financial can scale rapidly when provided with access to the right global trading markets, technology infrastructure and licenses available through Avrio and its ecosystem,” said Brian Foote, CEO of HUMBL. “This is the right home for HUMBL Financial to achieve its global scaling goals, while delivering brand recognition, equity and revenue share value for our HUMBL shareholders.”

To view the full press release, visit https://ibn.fm/a99Ph

About HUMBL Inc.

HUMBL is a Web3 platform with both a consumer and commercial division, focused on verified profiles and transactions. HUMBL offers consumer products such as the HUMBL Wallet(TM), HUMBL Search(TM), HUMBL Tickets(TM), HUMBL Web Platform (HUMBL.com) and more. For more information, visit www.HUMBL.com.

HUMBL Inc. (HMBL), closed Thursday's trading session at $0.0008, even for the day, on 167,531,299 volume. The average volume for the last 3 months is 75,801 and the stock's 52-week low/high is $0.0007/$0.0105.

Premier Products Group Inc. (PMPG)

Wolf of Penny Stocks, Journal Transcript, Epic Stock Picks and Elite Stock Alerts reported earlier on Premier Products Group Inc. (PMPG), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Premier Products Group (OTC: PMPG) has issued a letter to shareholders from interim CEO Terry L Stein. In the letter, Stein noted that the company has been trading on the “expert market” because of prior management’s failure to ensure that required filings were kept up to date, meaning that access to securities are only available to broker-dealers, professionals and sophisticated investors. Consequently, Stein filed a default against the management group and took over voting control of the company in an effort to protect shareholders and become compliant with the U.S. Securities Commission (“SEC”). The process has been time consuming, but Stein reassured stockholders that “we have worked as diligently as possible, and spent a considerable amount of resources, to complete these numerous tasks and protect the integrity of the company for the future — which in turn benefits all shareholders.” Stein reported that the auditor is completing work and the company is planning to file 2021, 2022, and 2023 annual financials to become fully compliant with SEC filing requirements; PMPG will then work with OTC Markets to return to trading. In addition, Stein noted that the company continues to move forward with its Smart Cities and Roadways business, anticipating expanding the offering and adding new artificial intelligence (“AI”) partners.

“This will require more funding for sure, but we feel confident we will be able to accomplish this in a timely manner once we are back on track,” said Premier Products Group interim CEO Terry L. Stein in the shareholder letter. “Also, we are working with two other exciting companies that we believe will bring value to our company going forward and look forward to making those announcements in the near future.”

To view the full press release, visit https://ibn.fm/VUzfY

About Premier Products Group Inc.

Premier Products Group engages in the acquisition of technology companies and develops SmartRoads and Smart City infrastructures. The company was founded on Nov. 14, 1979, and is headquartered in Woodland Hills, California. For more information, please visit www.wsj.com/market-data/quotes/PMPG/company-people.

Premier Products Group Inc. (PMPG), closed Thursday's trading session at $0.000001, even for the day. The average volume for the last 3 months is 63,437 and the stock's 52-week low/high is $0.000001/$0.001.

The QualityStocks Company Corner

Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB: ATBHF)

The QualityStocks Daily Newsletter would like to spotlightFathom Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB: ATBHF).

A maiden mineral resource estimate for the Storm Copper Deposit is anticipated to be released in Q1 2024; an expanded drilling program is planned for 2024 to significantly increase the resource, and work is already underway to advance the low capex open pit mining opportunity toward development.

In October 2023, the company closed a brokered private placement and a concurrent non-brokered private placement for proceeds of C$2.5 million.

In March 2021, the company entered an option agreement that allows American West Metals Limited to earn an 80% interest in Aston Bay's Storm Copper Project and Seal Zinc Deposit; America West is responsible for all exploration expenditures at Storm until completion of a bankable feasibility study.

Aston Bay continues to explore for high-grade discoveries in the down-dip and along-strike potential at its Buckingham Gold Project, as well as for the critical metals copper, zinc and cobalt throughout North America.

Aston Bay Holdings (TSX.V: BAY) (OTCQB: ATBHF) is a publicly traded Canadian minerals exploration company focused on exploring high-grade copper and gold deposits in North America. The company owns the Storm Copper Project and the Seal Zinc Deposit in Nunavut, Canada, and is currently exploring the Buckingham Gold Vein and critical metals prospects in central Virginia. Aston Bay is also in the advanced stages of negotiation on other properties with high-grade critical minerals potential in these areas.

Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB: ATBHF) is a publicly traded Canadian minerals exploration company focused on exploring high-grade copper and gold deposits in North America. The company owns the Storm Copper Project and the Seal Zinc Deposit in Nunavut, Canada, and is currently exploring the Buckingham Gold Vein and critical metals prospects in central Virginia. Aston Bay is also in the advanced stages of negotiation on other properties with high-grade critical minerals potential in these areas.

The company believes in responsible exploration and carries out its work programs to the highest standards of social responsibility, environmental stewardship and health and safety. Aston Bay cares about leaving a net positive impact on the communities in which it works and engages with local representatives, Indigenous groups and government agencies to build respectful relationships through dialogue and collaborative processes. Depending on the stage of exploration, these efforts may include employment, contracting, training, community benefits and other agreements.

Aston Bay conducts exploration through safe, socially and environmentally responsible and sustainable work practices. The company embeds core values of health and safety throughout its operations by adhering to strict health and safety standards and practices that meet and/or exceed industry standards and government codes and regulations.

The company is headquartered in Toronto.

Projects

Storm Copper

The high-grade Storm Copper Deposit is located 112 kilometers south of the community of Resolute Bay, Nunavut, on western Somerset Island, just south of the past-producing Polaris Pb-Zn Mine. The property comprises 173 contiguous mining claims, including the Storm Copper and Seal Zinc projects, covering an area of approximately 541,795 acres.

The property has good access to established shipping lanes, and the landscape provides favorable conditions for development of roads and a protected deep-water port. Exploration is supported through excellent infrastructure in the nearby hamlet of Resolute Bay.

Aston Bay is partnered with American West Metals (ASX: AW1) at Storm. American West is responsible for all exploration expenditures, having aggressively advanced the project toward production and earned an 80% interest. This affords excellent optionality to the company’s shareholders, as Aston Bay is free carried with no required expenditures until the completion of a bankable feasibility study.

American West recently completed an Australian JORC-compliant Maiden Resource Estimate for Storm; the North American 43-101 compliant resource estimate is expected in Q1 2024. American West is cashed up and plans a multimillion-dollar resource expansion and new discovery drilling program for the summer of 2024.

The Buckingham County Gold Project

The gold-bearing system at the Buckingham County Gold Project in Virginia lies within a belt hosting past producing mines, current gold mines and advanced gold explorations, stretching through Georgia, the Carolinas, Virginia, Nova Scotia and Newfoundland.

Buckingham hosts a “Kirkland Lake-style” high grade gold vein returning values consistently over one ounce gold per ton and is underexplored both at depth and along almost one mile of strike length. These types of veins have excellent ESG qualities, as they are typically mined using a small footprint underground method, with gold extracted using simple and environmentally friendly gravity methods.

Market Opportunity

The World Gold Council, the industry association for the world’s gold producers, estimated in 2023 the physical financial gold market, which is made up of bars, coins, gold ETFs and central bank reserves, is worth nearly $5 trillion. The council reports that gold mine production adds approximately 3,500 tons of the precious metal to the world’s supply annually, equivalent to about 2% growth.

This historical scarcity and relatively slow production of new supply, as compared to other commodities, is a primary reason gold has retained its value for millennia, according to the council.

A report from Acumen Research and Consulting, a global provider of market intelligence and consulting services, valued the global copper market at $304.1 billion in 2022 and forecast that it will reach a market size of $496.8 billion by 2032, growing at a CAGR of 5.1% over the forecast period.

The report identifies a growing demand for copper in the electronics industry, as well as an expanding copper supply due to increasing production from existing mines and the rising number of mine development projects in developing nations, as driving factors in the rising value of the copper market.

Management Team

Thomas Ullrich is CEO and Director of Aston Bay. He has over 30 years of experience in mineral exploration and geoscience. Before joining Aston Bay, he was Chief Geologist North America for Antofagasta Minerals plc, investigating copper potential through extensive property evaluations and management of drill programs in the United States, Mexico and Canada. Prior to that, he was Senior Geologist for Almaden Minerals.

Sofia Harquail handles Investor Relations and Corporate Development at Aston Bay. She has over 15 years of experience in the private and public sectors of the mining industry. Before joining Aston Bay, she worked as a consultant for the Prospectors and Developers Association of Canada and for exempt market dealer Red Cloud Financial Services Inc. Ms. Harquail holds an M.A. from the University of Uppsala in Sweden and received her CPIR designation from the CIRI/Ivey Investor Relations Program. She also sits on the board of the Young Mining Professionals Toronto and is CSC Certified.

Aston Bay has a talented Board of Directors bringing broad experience from across the industry, encompassing resource expansion, mine development, mergers and acquisitions, and mining finance.

Ms. Jessie Liu-Ernsting has over 15 years of experience in the mining industry, spanning capital projects engineering, debt capital markets, private equity and corporate strategy at several firms, including Hudbay Minerals and Resource Capital Funds. She is currently VP Investor Relations and Communications at G Mining Ventures Corp.

Mr. Jeffrey R. Wilson has over 25 years’ experience in the mining industry, having served as a director, officer and advisor of multiple public and private companies in the mineral exploration and mining investment industries. Mr. Wilson is currently President & CEO of Precipitate Gold Corp.

Mr. Gary O’Connor has over 40 years of diverse experience as a mineral exploration and development professional in the management of successful resource projects as well as the evaluation, technical due diligence, and supervision of large mineral exploration and development projects through-out the world. While with Freeport, Mr. O’Connor worked on the due diligence and discovery of a major gold fraud on the Busang gold “deposit” in Kalimantan by Bre-X.

Mr. Mark J. Pryor is a geologist with a 40-year track record of successfully advancing multiple precious metal, copper, coal, REE and Li projects from discovery through to exploitation. He is currently Executive Vice President of the Exploration Division at The Electrum Group.

Aston Bay Holdings Ltd. (OTCQB: ATBHF), closed Thursday's trading session at $0.087, up 3.5714%, on 2,000 volume. The average volume for the last 3 months is 88,561 and the stock's 52-week low/high is $0.0177/$0.2474.

Recent News

SOBRsafe Inc. (NASDAQ: SOBR)

The QualityStocks Daily Newsletter would like to spotlightFathom SOBRsafe Inc. (NASDAQ: SOBR).

SOBR Safe (NASDAQ: SOBR) ("SOBRsafe(TM)"), a provider of next-generation transdermal alcohol detection solutions, today announced that the Oglala Lakota Nation is adopting the SOBRcheck(TM) technology for use in its community-wide probation management program. The Oglala Lakota Nation is a self-governing nation within the U.S., and its Pine River Reservation in South Dakota is the eighth-largest Native American reservation in the country. "Our law enforcement function is resource-constrained, so we are always seeking ways to innovate and gain operational efficiencies," said Warren Cross, lab director, Oglala Sioux Tribe Clinical Lab. "SOBRcheck is faster and cleaner than the legacy breathalyzer method, both freeing up staff time and creating a safer work environment. Moreover, it brings dignity to detection in a tightly knit community. We don't seek to embarrass our friends and neighbors - SOBRcheck helps remove that emotion from the alcohol screening process."

To view the full press release, visit https://ibn.fm/aNpvV

SOBRsafe Inc. (NASDAQ: SOBR) is a provider of a game-changing transdermal (touch-based) alcohol detection technology that can improve workplace safety and provides advanced screening and monitoring solutions for the behavioral health industry.

Alcohol misuse is the fourth leading cause of preventable death in the U.S., and the seventh worldwide. Nearly half of all industrial accidents with injuries are alcohol-related, and 1-in-10 U.S. commercial drivers tests positive for alcohol – the highest rate in the world. Despite these statistics, prevention and monitoring solutions have not kept pace with this epidemic. Legacy detection technologies are invasive and inefficient, unhygienic and unconnected. SOBRsafe believes there is a better way.

The company has developed a patent-pending alcohol detection device called SOBRcheck™ for use in detecting alcohol in humans, with just the touch of a finger. SOBRsafe’s next-generation transdermal technology detects and instantaneously reports the presence of alcohol as emitted through a user’s skin. No breath, blood or urine sample is required. SOBRsafe believes its technology is a superior, hygienic alternative to traditional breathalyzers for frontline, preventative applications.

With a powerful backend data platform, SOBRsafe provides humane, passive and connected alcohol detection for the behavioral health, transportation, oil and gas, judicial and consumer markets.

A preventative solution in historically reactive industries, SOBRsafe technology is being deployed for commercial fleets, workplaces, alcohol rehabilitation, probation management and teen drivers. This monitoring technology helps prevent intoxicated workers from taking the factory floor or drivers from receiving the keys to a truck, bus or family car. An offender is immediately flagged, and an administrator is empowered to take the appropriate corrective actions.

SOBRsafe technology is commercially available for access control (SOBRcheck), wearable use (SOBRsure™) and licensing or white labeling.

The company is headquartered in the Denver (CO) Technology Center.

Products

The SOBRsafe technology is integrated within the company’s robust and scalable data platform, producing statistical and measurable user and business data.

SOBRsafe™

With a mission is to save lives, increase productivity, create significant economic benefits and positively impact behavior, SOBRsafe developed the scalable, patent-pending SOBRsafe™ platform for non-invasive alcohol detection, real-time reporting and historical data aggregation.

SOBRsafe is a solution that has broad applications in behavioral health, fleet and facility safety, youth drivers and judicial markets.

SOBRcheck™

SOBRcheck is the company’s stationary identification and alcohol monitoring product, providing a quick, specific-point-in-time test for the presence of alcohol. In hygienic, real-time fashion, SOBRcheck verifies user identity and determines the absence or presence of alcohol.

SOBRcheck provides an administrator immediate results – delivered securely – to aid in the efficient management of an existing substance abuse policy.

SOBRsure™

SOBRsure is the company’s transdermal, alcohol-detecting wearable. SOBRsure provides continuous, mobile alcohol monitoring. The band’s advanced alcohol safety technology discreetly detects and instantaneously reports the presence of alcohol in the body. Additionally, SOBRsure provides app-based alcohol detection alerts, pinpoint location tracking and band-removal notifications.

The SOBRcheck and SOBRsure revenue models consist of two components: (1) a hardware device purchase and (2) a recurring monthly SaaS subscription fee.

Design, manufacturing, quality testing and distribution for all SOBRsafe devices takes place in the U.S.

 

Market Opportunity

A report from Data Bridge Market Research, an international market research and consulting firm, estimated the global alcohol sensor market at $2.3 billion in 2022. The market is forecast to reach a value of $6.3 billion by 2030, recording a CAGR of 13.7% over the forecast period.

Market growth drivers, as cited by the report, include rising alcohol consumption rates, more stringent laws pertaining to alcohol consumption and new, more effective technologies that facilitate detection and enforcement.

Greater awareness of alcohol consumption as a potential threat to public and workplace safety has led to increased emphasis on preventing operation of motor vehicles and machinery by those under the influence of alcohol and promoting responsible alcohol consumption, as the report details.

Management Team

David Gandini is Chairman and CEO of SOBRsafe. He most recently served as president of IPS Denver, a bank card personalization company. Prior to that, Dave was the COO at First World Communications, a U.S. internet and data center provider, and participated in its successful IPO. He previously founded Pace Network Services and facilitated a successful exit to ICG Communications. Dave also co-founded Detroit-based Digital Signal in the fiber optic long haul market sector, where he executed a successful exit to SP Telecom.

Chris Whitaker, CPA, is CFO of SOBRsafe. Previously, Chris had served as the Company’s Vice President of Finance and Accounting. He has held various executive finance positions with large public multi-national corporations and small entrepreneurial companies throughout a progressive 30-year career that began with KPMG. Chris was formerly President – Americas and Vice President of Finance and Administration for public, multinational corporation Elixinol. He also served as the Managing Director of AEGIS Financial Consulting, leading a team of consultants in providing fractional CFO and financial consulting services to a wide variety of businesses in the public and private sectors.

Scott Bennett is EVP, Business Operations at SOBRsafe. He has more than 20 years of experience as a senior executive in technology-driven enterprises. Prior to joining SOBRsafe, he co-founded cybersecurity firm GBprotect and served as its COO until its successful sale to Nuspire. He previously served as Chief Technical Officer/Chief Information Security Officer of fintech businesses Catalyst Card Company and Integrated Printing Solutions.

SOBRsafe Inc. (NASDAQ: SOBR), closed Thursday's trading session at $0.6216, up 2.5743%, on 30,957 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.2474/$.

Recent News

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI)

The QualityStocks Daily Newsletter would like to spotlight Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI).

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing inflammation and immunology ("I&I") biological products and providing CDMO services through its Scinai Bioservices business unit, today announced that it will be attending the MIXiii International Life Science and Health-tech Conference. The event is slated to take place March 5 and 6 in Jerusalem. Several members of Scinai's leadership team will be available for discussions with prospective clients of the company's end-to-end biologics CDMO service, potential pharmaceutical industry partners to advance Scinai's innovative NanoAb pipeline, and investors interested in SCNI's value proposition. Scinai also announced its planned participation in the Bio Europe Spring conference in Barcelona on March 18 to 20. Details are listed in the events section of Scinai's website.

To view the full press release, visit https://ibn.fm/lhXta

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) is a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious diseases and autoimmune diseases.

In collaboration with the prestigious Max Planck Institute for Multidisciplinary Sciences (MPG) and the University Medical Center Göttingen (UMG), both in Germany, Scinai is developing a pipeline of innovative nanosized antibody (NanoAb) therapies addressing diseases underserved by current treatments and with large and growing markets, such as COVID-19, asthma and psoriasis.

NanoAbs, also known as VHH-antibodies or Nanobodies, are alpaca-derived nanosized antibodies that exhibit multiple significant competitive advantages over existing antibody therapies, including stability at high temperatures, superior binding affinity, more effective and convenient routes of administration and efficient production. Scinai is uniquely positioned to advance nanosized antibody innovation from R&D through commercialization.

The company’s highly experienced and successful pharmaceutical industry leadership team includes former senior executives from Novartis, GSK and Bristol-Myers Squibb.

Since its founding, Scinai has executed eight clinical trials, including a seven-country, 12,400-participant Phase 3 trial of a prior influenza vaccine candidate, and it built, owns and operates a 20,000 sq. ft. state-of-the-art GMP biologics manufacturing facility housing its laboratories, production facilities and offices.

Lead Candidate: Inhaled COVID-19 NanoAb

In December 2021, Scinai signed definitive agreements with the Max Planck Society – parent organization of the Max Planck Institute for Multidisciplinary Sciences– and the UMG to enter a strategic collaboration for the development and commercialization of innovative COVID-19 NanoAbs.

The company is planning a rapid development path that leverages its expertise and capabilities in biological drug development and manufacturing. Scinai anticipates preclinical proof-of-concept results for an inhaled COVID-19 NanoAb by the end of 2022, with initial Phase 1/2a human clinical trial results expected in 2023.

The intended inhaled mechanism of delivery of Scinai’s COVID-19 NanoAb formulation may serve as a significant differentiator when compared to approved monoclonal antibodies, which are injected. Inhaled delivery has shown to be cheaper, more convenient and likely safer for patients and providers.

NanoAb Pipeline: Psoriasis, Asthma and More

The COVID-19 NanoAb development agreement is part of a broader five-year research collaboration agreement signed in March 2022 covering discovery, development and commercialization of NanoAbs for several other disease indications with large market medical needs, including asthma, psoriasis, macular degeneration and psoriatic arthritis.

Scinai has an exclusive worldwide license for development and commercialization of COVID-19 NanoAbs and exclusive options for similar worldwide licenses for NanoAbs for the above mentioned additional large market disorders currently underserved by approved therapeutic antibodies.

Academic research teams from MPG and UMG have verified strong affinity by the new NanoAbs to their biological target molecules and high thermostability. They have also demonstrated strong neutralization by several NanoAb candidates of their respective target molecules. Neutralization studies of the other NanoAbs are expected to begin later in 2022.

Based on the promising results, Scinai will focus development efforts beginning with the following NanoAbs:

  • NanoAbs targeting IL-17 as drug candidates for the potential treatment of psoriasis and psoriatic arthritis
  • NanoAbs targeting IL-13 and NanoAbs targeting TSLP as drug candidates for the potential treatment of asthma

These are conditions for which the antibody target is validated by existing treatments and the mechanism of action is well understood. Both represent large medical needs and growing markets. Scinai anticipates preclinical proof-of-concept for at least one of these NanoAbs in 2023. This is in addition to the aforementioned human clinical Phase 1/2a for the inhaled COVID-19 NanoAb therapy, which is also anticipated in 2023.

CDMO Services

While NanoAb pipeline development is Scinai’s core focus, the company also offers its cGMP manufacturing facility, aseptic fill and finish suite, laboratories and experienced professionals for contract development and manufacturing organization (CDMO) services. This offering is designed to keep the Scinai team abreast of the latest industry developments and trends while building experience and generating revenue to support the company’s NanoAb pipeline development.

Market Opportunity

COVID-19 treatment, target of the company’s lead NanoAb therapy candidate, had an estimated market size of $22 billion in 2021.

Future Scinai drug candidates will target conditions with large markets growing at attractive CAGRs.

The global asthma treatment market was valued at $18.08 billion in 2019 and is projected to reach $26.01 billion by 2027, exhibiting a CAGR of 4.5% during the forecast period, according to Fortune Business Insights. The research firm predicts that the global psoriasis treatment market will grow from $26.37 billion in 2022 to $47.24 billion by 2029, exhibiting a CAGR of 8.7% over the forecast period.

Management Team

Amir Reichman is Scinai’s CEO. He previously was Head of Global Vaccines Engineering Core Technologies at GSK Vaccines in Belgium. Prior to that, he held leadership roles at Novartis Vaccines’ Global Vaccines Supply Chain Management organization. He was the first employee of NeuroDerm Ltd., a company focused on transdermal drug delivery, and served as Senior Scientist until his departure in 2009. He earned a M.Sc. in Biotechnology Engineering from Ben-Gurion University and an MBA in Finance and Health Care Management from the University of Pennsylvania’s Wharton School.

Tamar Ben-Yedidia, Ph.D., is Chief Science Officer at Scinai. She has more than 30 years of experience in immunology, with specific expertise in the development of vaccines. She began her career with Biotechnology General Ltd., working on development of a recombinant Hepatitis-B vaccine. She later joined the Weizmann Institute of Science, working on the design of a peptide-based vaccine against several pathogens. She is widely published, with numerous refereed articles and invited reviews in various scientific journals. She received her Ph.D. from the Weizmann Institute.

Elad Mark is COO at Scinai. He has over 15 years of biotechnology industry experience encompassing diverse project stages including feasibility studies, conceptual and detailed design, commissioning, qualification and process validation. Prior to joining Scinai, he led Novartis’s $800 million investment in a biologics facility in Singapore. With Biopharmax and Antero, both global pharmaceutical engineering companies, he successfully led projects in Israel, China and Singapore. He holds a BSc. in Engineering from the Afeka Tel Aviv Academic College of Engineering and an MBA from the Open University of Israel.

Uri Ben-Or is CFO at Scinai. He has served as CFO with public life science companies traded on the TASE, OTC and Nasdaq. Ben-Or provides his services to Scinai through CFO Direct, a company he founded and for which he serves as CEO. He served as the VP of Finance of Glycominds, a leading biotechnology company, and as CFO of a spin-off from Telrad Networks. He also served as a Corporate Controller at Menorah Capital Markets and as an Auditor at PWC. He holds a B.A. in Business from the College of Administration, an MBA from Bar-Ilan University, and is a CPA.

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), closed Thursday's trading session at $0.4909, up 3.3474%, on 28,289 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.46/$2.44.

Recent News

Zoned Properties Inc. (OTCQB: ZDPY)

The QualityStocks Daily Newsletter would like to spotlightFathom Zoned Properties Inc. (OTCQB: ZDPY).

Zoned Properties®, Inc. ("Zoned Properties" or the "Company") (OTCQB:ZDPY), a leading real estate development firm for emerging and highly regulated industries, including legalized cannabis, today announced that the Company has acquired an investment property in Chicago, Illinois (the "Investment Property") and entered into a long-term, absolute-net lease agreement with Justice Cannabis Co.'s BLOC Dispensaries to operate a Retail Dispensary.

"This investment significantly enhances our property investment portfolio and rental revenue base, and diversifies our tenant roster. We have partnered with a best-in-class cannabis operator, which underscores the highest and best use of this premier retail location. Illinois is home to one of the most exciting, emerging cannabis markets in the nation with strong consumer brands and growing consumer demand. Driven by robust consumer brands and escalating demand, Illinois' market has reached new heights with the Department of Financial and Professional Regulation (IDFPR) reporting a surge in retail activity, including the launch of 28 new dispensaries and total dispensary sales eclipsing the $1.5 billion mark in FY23. We are poised to play a pivotal role in the commercial real estate landscape of the cannabis sector and this partnership aligns with the Company's mission to innovate within the real estate development sector, driving growth and delivering value to shareholders," commented Bryan McLaren, Chief Executive Officer of Zoned Properties. "The collaboration with Justice Cannabis Co.'s BLOC Dispensaries is a testament to our strategic vision and we look forward to expanding our relationship with their executive team."

Transaction Highlights

Zoned Properties has acquired a premier Investment Property in Chicago, Illinois that has been entitled and permitted as a cannabis retail dispensary.

The Investment Property was acquired for approximately $1.6 million, including all closing costs and fees. The transaction also includes a commitment from the tenant's operating partner of up to $1 million for renovation and construction improvements.

The Investment Property is leased to Justice Cannabis Co.'s BLOC Dispensaries under a long-term, absolute-net lease agreement, which will produce an approximate 16.5% Cap Rate when straight-lined over the 15-year term of the lease agreement. The lease includes 3% annual increases in base rent over the life of the lease term, yielding approximately $265,000 in annual base rental revenue when straight-lined over the life of the lease term.


Zoned Properties Inc. (OTCQB: ZDPY) is a technology-driven property investment company focused on acquiring value-add real estate within the regulated cannabis industry in the United States. The company aspires to innovate within the real estate development sector, focusing on direct-to-consumer real estate that is leased to best-in-class cannabis retailers.

The company is redefining the approach to commercial real estate investment through its standardized investment process backed by its proprietary property technology. Zoned Properties has developed a national ecosystem of real estate services to support its real estate development process, including a commercial real estate brokerage and a real estate advisory practice.

With a decade of national experience and a team of experts devoted to the emerging cannabis industry, Zoned Properties is addressing the specific needs of a modern market in highly regulated industries. The company targets commercial properties that face unique zoning or development challenges, identifies solutions that can potentially have a major impact on their commercial value and then works to acquire the properties while securing long-term, absolute-net leases.

Zoned Properties targets commercial properties that can be acquired and rezoned for specific purposes, including the regulated and legalized cannabis industry. It does not grow, harvest, sell or distribute cannabis or any substances regulated under United States law.

The company is headquartered in Scottsdale, Arizona.

Portfolio

The company’s investment properties are located in Arizona, Michigan and Illinois, with 100% occupancy and a weighted average lease term over 10 years. Each of the company’s leased properties is occupied by a commercial cannabis tenant. The company is expecting rental revenue from its property investment portfolio of greater than $2.5 million in calendar-year 2024.

Zoned Properties maintains a portfolio of properties that it owns, develops and leases. As of February 2024, the company leases land and/or building space at the six properties in its portfolio to licensed and regulated cannabis tenants in areas with established cannabis regulations and zoning procedures. Four of the leased properties are zoned and permitted as regulated cannabis retail dispensaries, and two of the leased properties are zoned and permitted as regulated cannabis cultivation and processing facilities.

The company considers the two cultivation sites in its portfolio as legacy properties and may consider selling or leveraging those properties to unlock equity and create capital availability in the future. The Zoned Properties investment thesis has evolved over the years as the cannabis industry has emerged, and the company is currently focused on investing capital into direct-to-consumer properties, located in state-markets with robust cannabis consumer demand in the industry.

Zoned Properties is in pursuit of property acquisitions that can be characterized as consumer-facing, retail dispensary properties that are positioned to be leased to retail dispensary cannabis tenants under net leasing structures. As of September 2023, the company has agreements in place to acquire new investment properties with new cannabis tenants located in Arizona, Missouri and Illinois. The company plans to initiate and target its investment process in Ohio and Maryland.

With a strategic shift in focus to direct-to-consumer real estate that is leased to best-in-class cannabis retailers in the industry, the company will continue to utilize its competitive edge when identifying excellent investment properties. Zoned Properties has a full pipeline of acquisition prospects and continues to utilize an extremely disciplined capital allocation approach.

Market Opportunity

According to MJBizDaily, a publication that has covered the North American cannabis business since 2011, combined U.S. medical and recreational cannabis sales were estimated at approximately $33.6 billion at the end of 2023, largely driven by the opening of new adult-use markets.

The publication projects that combined U.S. retail cannabis sales will reach upwards of $53.5 billion by 2027, according to an analysis published in its volume of cannabis market research, the MJBiz Factbook.

As of February 2024, 38 U.S. states had legalized medical, recreational or other limited use of cannabis. The Pew Research Center reports that, in January 2023, there were more than 11,000 licensed cannabis dispensaries in the U.S. In addition, global research firm IBISWorld reports that more than 40,000 U.S. localities have adopted regulations governing cannabis usage, production, processing and/or dispensing.

Management Team

Bryan McLaren is the Chairman and CEO of Zoned Properties. Previously, he worked as a Sustainability Consultant for Waste Management Inc., where he led the strategic development and operational implementation of zero-waste programs for clients. He was also appointed as a city Sustainability Commissioner. He holds a bachelor’s degree in business administration from the University of San Diego, a master’s degree in sustainable development from Northern Arizona University, an executive master’s degree in business leadership from Arizona State and an MBA with a specialty in sustainable development.

Berekk Blackwell is the President and COO of Zoned Properties. He previously spent time in developing domestic and international markets for Kahala Brands, a conglomerate of over 15 QSR franchises, including Cold Stone Creamery and Blimpie Subs. He later worked on developing QSR concepts for Revamp Corp. in Tokyo. After returning to the U.S., he served as president of Daily Jam, a limited-service breakfast and brunch chain. He holds a bachelor’s degree in business administration in finance from Fort Lewis College.

Patrick Moroney is the Director of Real Estate Acquisitions for Zoned Properties. Previously, he was one of the most successful Associate Brokers at Kidder-Mathews, focusing primarily on the regulated cannabis industry. He also worked as a commercial real estate broker rep at Cushman & Wakefield and Colliers International. He graduated from Arizona State University, after which he spent four years as a local sports broadcaster in Georgia and Iowa.

Kyle Gere is the Director of Advisory Services at Zoned Properties. He has years of licensing experience across multiple U.S. states in the medical and recreational cannabis markets. Since 2015, he has been involved in cannabis real estate transactions in Arizona and Michigan, managing a portfolio of medical marijuana properties. He attended Northern Arizona University, graduating with a bachelor’s degree in business administration in both management and marketing.

Zoned Properties Inc. (OTCQB: ZDPY), closed Thursday's trading session at $0.5, up 9.1703%, on 14,660 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.35/$0.80.

Recent News

Turbo Energy S.A. (NASDAQ: TURB)

The QualityStocks Daily Newsletter would like to spotlight Turbo Energy S.A. (NASDAQ: TURB).

Turbo Energy (NASDAQ: TURB), a designer, developer and manufacturer of photovoltaic energy generation, management and storage equipment, has sought to take advantage of the dramatic increase in renewable energy demand, which has been driven by the decline in renewable energy costs and the exponential rise in fossil fuel prices. "Turbo Energy has looked to capitalize on the growing transition toward renewable energy and sustainable residential energy supplies through its revolutionary ‘SunBox Home' energy storage solution. The company's ‘SunBox Home' system encompasses an all-in-one AI-powered energy storage solution, designed to assist households in managing their power consumption. Directly linked to a household's solar panel generation unit, the SunBox system allows users to choose between settings including ‘maximum consumption' or ‘maximum savings,' conserve a portion of its energy reserves in the event of unexpected electricity blackouts or rather, sell excess power back into the grid. The groundbreaking energy storage system additionally boasts the capacity to track weather forecasts, thus ensuring its batteries are fully charged in the event of a storm," a recent article explains.

To view the full article, visit https://ibn.fm/xz6qu

Turbo Energy S.A. (NASDAQ: TURB) designs, develops and distributes equipment for the generation, management and storage of photovoltaic energy in Spain, Europe and internationally.

Turbo Energy’s products include lithium-ion batteries and inverters. Additionally, the company recently launched its flagship product, the Sunbox, an all-in-one device that integrates most of the equipment required for a residential photovoltaic installation. The Sunbox is powered by AI and features a software system that monitors the generation, use and management of photovoltaic energy by analyzing large amounts of data related to energy generation, consumption, market prices and weather forecasts. This AI system optimizes battery usage, reducing electricity bills and providing peak-use reduction and uninterruptible power supply functions.

Turbo Energy currently sells its photovoltaic energy equipment primarily through distributors for residential consumers in Spain, but it possesses the expertise and international perspective to expand its product portfolio into industrial and commercial scale and markets, as well as advancing the internationalization process it has already started. The company plans to expand into the industrial photovoltaic sector with its new Sunbox, launched in 2023, in higher power and capacity variants. Its goal is to become a significant player in this sector and contribute to the growth of renewable energy solutions.

The company was incorporated in 2013 and is based in Valencia, Spain. It operates as a subsidiary of Umbrella Solar Investment S.A.

Products

Lithium-Ion Batteries

Turbo Energy is one of the leading companies that introduced lithium-ion batteries for photovoltaic energy storage in Spain. Primarily for the home energy storage market, the company’s batteries have capacities from 2.24 kWh to 5.1 kWh in 24 and 48 volts. In addition, its 48V / 5.1 kWh units are available in a dual battery system.

Inverters

The inverter converts the direct current produced by the photovoltaic panels into alternating current that can be used by household appliances. It also regulates battery charging and discharging based on energy needs and optimizes utilization of generated renewable energy. Turbo Energy currently offers multiple models that cover most household installations.

All-in-One Sunbox

This product incorporates inverters, batteries and the rest of the components necessary to operate and protect the photovoltaic installation. This saves installation cost and assembly and configuration time while preventing errors. Notably, the latest Sunbox models also offer an EV charging option.

Software System

In communication with the inverter, the company’s software monitors energy flows between the photovoltaic panels, household consumption, storage and an optional electric vehicle charging station. The software allows users to customize an automatic backup mode based on weather forecasts, or manually select which part of the battery will be reserved for possible power outages. It also allows the battery to be used in a peak shaving mode, which leverages AI to trigger battery power when grid energy is most expensive, effectively reducing the amount of high-cost power drawn from the grid.

Market Opportunity

According to a report by Fortune Business Insights, a global research and reporting firm, the solar energy storage battery market was estimated to be worth $3.33 billion in 2022 and is projected to reach a value of more than $20 billion by 2030, marking a CAGR of 24.2% over the forecast period.

These batteries are crucial components of renewable energy systems, allowing for the storage of excess electricity generated by solar panels, so it can be used during times of no or low sunlight. By storing energy and supplying it when needed, these batteries reduce reliance on the power grid and maximize self-consumption while helping users avoid peak electricity rates. They also contribute to the transition toward a cleaner and more sustainable energy future by enabling residential consumers and businesses to use solar power even when the sun is not shining.

Management Team

Enrique Selva Bellvís is the CEO and founder of the Umbrella Group. In addition, he serves as vice-president of the Valencian Association of Energy Sector Companies industry group. Before his career in the solar energy sector, he was the founder and CEO of Innova Ingenieros Consultores. He holds a degree in industrial engineering with a specialization in energy from the Polytechnic University of Valencia and completed the Management Development Programme at the IESE Business School.

Mariano Soria is the Chief Innovation Officer for the Umbrella Group and serves as General Manager of Turbo Energy. He was CEO of Punt Moble XXI S.L. and continues to serve on that company’s board. Before that, he was the General Manager of REJMAR S.A., a land development company. He received his degree in industrial engineering and industrial organization from the Polytechnic University of Valencia, and his MBA from the European University of Madrid.

Alejandro Moragues is CFO of Turbo Energy. Previously, he held the position of Senior Corporate Auditor for U.S. company Euronet Worldwide Inc. and was an external auditor for PricewaterhouseCoopers. He holds a bachelor’s degree in business administration and management from the Polytechnic University of Valencia.

Manuel Cercos is Chief Commercial Officer at Turbo Energy. Previously, he held positions at Técnicas Aplicadas en Baterías S.L., where he served as Sales Director and Sales Manager. Before that, he worked as a Sales Technician at DAISA.

Turbo Energy S.A. (NASDAQ: TURB), closed Thursday's trading session at $1.2, up 0.840336%, on 4,146 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.855/$7.90.

Recent News

Mullen Automotive Inc. (NASDAQ: MULN)

The QualityStocks Daily Newsletter would like to spotlight Mullen Automotive Inc. (MULN).

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle ("EV") manufacturer, has moved to the next phase in testing an integrated solid-state polymer battery pack in its Class 1 EV cargo vans. According to the announcement, vehicle road testing began this week on the battery pack. The company began initial lab testing of the latest phase of solid-state polymer battery packs in January by installing the battery pack in the Class 1 EV cargo van to monitor system compatibility between the vehicle and pack; performance testing also included on-road drive cycles and Dyno testing at an EPA-certified lab. The company initially estimated that the battery pack would result in a 73% increase range of the EV, from 110 miles to 190 miles; however, testing has shown an actual 86% increase in vehicle range from 110 miles to 205 miles. "The first road test has resulted in significant gains in vehicle range," said Mullen Automotive CEO and chair David Michery in the press release. "Additional testing over time will solidify a solid-state solution for our commercial vehicles. Next steps include finalizing our design and manufacturing validation."

To view the corresponding image, visit https://ibn.fm/zr9oH

To view the full press release, visit https://ibn.fm/7JSGB

Mullen Automotive Inc. (NASDAQ: MULN) is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership.

Commencement of Trading on Nasdaq

On November 5, 2021, Mullen announced its commencement of trading on the Nasdaq Capital Market.

“Today is a monumental day for Mullen Automotive. I am especially proud of our team, investors and all who have believed in Mullen and taken us to this point as a publicly traded company on the Nasdaq Capital Market,” David Michery, CEO and Chairman of Mullen Automotive, stated in the news release. “Trading on Nasdaq now opens us up to new investors, both institutional and retail shareholders, and broadens our awareness and company profile, while increasing awareness of Mullen and our technology platform and opening new opportunities in EV and beyond. The road ahead has never been brighter for Mullen, and I am proud to lead us into the future.”

The milestone came in the wake of the company’s stock-for-stock merger with Net Element Inc.

The Mullen FIVE

The Mullen FIVE EV Crossover, debuting at the Los Angeles International Auto Show (LAIAS) on November 17, 2021, embodies Mullen’s Southern California roots with an inspired design focused on two complementary Golden State themes – California landscape and California urban.

The FIVE is built on an EV Crossover skateboard platform that offers multiple powertrain configurations and trim levels in a svelte design that is Strikingly Different™ and exciting to experience in person.

Prior to the start of LAIAS, the Mullen FIVE was selected as a finalist by the LA Auto Show for Top EV SUV in the ZEVA “People’s Choice” Awards.

LAIAS provides Mullen an opportunity to display multiple variants of the FIVE model while also showcasing its powertrain, battery and charging technology. The company intends to bring the FIVE to market in 2024, and reservations are currently open here.

Mullen’s development portfolio also includes EV Fleet Vans, which it intends to bring to market in Q2 2022, and the pure electric, high performance Mullen DragonFLY.

Expansion of Manufacturing Capacity

On November 2, 2021, Mullen announced plans to expand its facility in Robinsonville, Mississippi.

Mullen’s Advanced Manufacturing and Engineering Facility (AMEC) currently occupies 124,000 square feet of manufacturing space. The total available land on the property is over 100 acres, and Mullen is moving ahead with plans to build out another 1.2 million square feet of manufacturing space to support class 1 and class 2 EV cargo vans and the Mullen FIVE EV Crossover.

On the expanded site, Mullen plans to build a body shop, a fully automated paint shop and a general assembly shop.

EV Market Outlook

The global EV market was reported to consist of 3,269,671 units in 2019, a figure that is expected to grow at a CAGR of 21.1% through 2030 to a total of 26,951,318 units worldwide. This market’s monetary value was estimated at $162.34 billion in 2019 and is expected to grow at a CAGR of 22.6%, resulting in an approximate value of $802.81 billion by 2027. The primary driver for this exponential growth is a worldwide increase in vehicle emissions regulations.

Management Team

David Michery is the CEO and Founder of Mullen and has been leading the company and its divisions since inception in 2014. With over 25 years of executive management, marketing, distressed assets, and business restructuring experience, Mr. Michery brings a wealth of relevant knowledge and expertise to the Mullen brand. He has notably created 12 trademarks so far to develop the company brand and vision.

Mr. Michery is working toward a sustainable future accessible to all by creating a suite of clean-energy electric vehicles at varied price points. With entirely U.S.-based manufacturing and operations, he is also determined to have Mullen Technologies play a role in shaping a self-sustaining local economy by creating more jobs in America.

Mr. Michery manages risks and company expectations as a pathway to success and has personally overseen several businesses that totaled over $1 billion in transactions. His key strength is the ability to be fiscally responsible and lead teams to complete projects on time and within budget. As a seasoned professional in this space, Mr. Michery has demonstrated skill in building businesses from the ground up and into successful entities that subsequently sold for hundreds of millions of dollars.

Mullen Automotive Inc. (MULN), closed Thursday's trading session at $7.12, up 0.140647%, on 538,765 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $6.36/$5573.25.

Recent News

Vision Marine Technologies Inc. (NASDAQ: VMAR)

The QualityStocks Daily Newsletter would like to spotlight Vision Marine Technologies Inc. (NASDAQ: VMAR).

Vision Marine Technologies (NASDAQ: VMAR), a global leader and innovator in the performance electric recreational boating industry, was spotlighted in a recent InvestorPlace article titled "Three Electric Boat Stocks That Will Sail Higher by 2024." "The article calls Vision Marine a key player in the electric boat stocks market, noting that despite some challenges, the company's recent ‘strategic moves suggest a promising future...' The article noted VMAR's partnership with 4ocean, along with its expansion into the pontoon market, which shows ‘strategic diversification' a move that InvestorPlace says ‘could be a game changer for Vision Marine, showcasing its adaptability and innovation in the market," reads a recent article, which contains excerpts from the InvestorPlace piece. "[InvestorPlace] observes that ‘the company's acquisition of industrial tooling to enhance its production capabilities is a strategic step. It aims to support the production of over 10,000 battery packs annually, meeting the increasing demand for electric marine propulsion systems. Despite financial headwinds, Vision Marine Technologies is positioning itself as a forward-thinking leader in the electric boat industry.'"

To view the full article, visit https://ibn.fm/QefkL

Vision Marine Technologies Inc. (NASDAQ: VMAR) is a global leader and innovator within the performance electric recreational boating industry. The company is engaged in designing and manufacturing electric outboard powertrain systems and related technology. It strives to be a guiding force for change and an ongoing driving factor in fighting the problems associated with waterway pollution by disrupting the traditional boating industry with electric power, in turn directly contributing to zero pollution, zero emission and a noiseless environment.

Vision Marine manufactures hand-crafted, highly durable, low maintenance, environmentally friendly electric recreational powerboats. The company’s business segments include the sale and rental of electric boats, with the majority of its revenue attributable to electric boat sales.

The designs and technology applied to Vision Marine’s boats result in enhanced performance, higher speeds and longer range. Put simply, Vision Marine boats offer a smoother ride than a traditional internal combustion engine motorboat.

The company is headquartered in Montreal.

Products

Vision Marine’s flagship E-Motion™ 180E electric marine powertrain is the first fully electric outboard powertrain combining advanced battery pack, inverter and high efficiency motor with proprietary union assembly between the transmission and motor. Vision Marine’s E-Motion and related technologies in this system utilize extensive control software and are uniquely designed to improve the efficiency of the outboard powertrain. As a result, both range and performance are enhanced.

More than a powerful electric outboard motor, the 180E is a complete powertrain package. The high-tech, marine-specific motor is equipped with multi-sensor captors and independent cooling, providing 180 horsepower.

An onboard charging system allows for quick and easy charging from any shore outlet, whether the vessel is in or out of the water. It implements cutting-edge marine battery packs that are IP67 certified and built to withstand the harshest marine environments. The system is glycol cooled with a controlled heat exchanger, ensuring optimal performance and longevity. A stainless-steel casing protects the battery from corrosion and physical damage over time.

The 180E is built to be integrated with many boat models produced by other marine manufacturers. Since boat manufacturers rarely build their own engines, instead choosing to source them from engine manufacturers, Vision Marine believes the 180E propulsion system can in the future end up powering nearly every recreational boat.

Market Opportunity

According to a report from Future Market Insights, a certified market research organization, the global electric boats market is expected to grow from a value of $5.6 billion in 2023 to $15.1 billion by 2033, achieving a CAGR of 10.4% during the forecast period.

Factors driving growth include rising seaborne commerce activities, a flourishing marine tourism industry and stringent emissions regulations aimed at reducing pollution. In addition, government support for electric speedboat adoption, advances in technological development and research and forecast expansion of needed charging infrastructure are credited as growth drivers.

An emphasis on reducing carbon emissions and encouraging consumer adoption of eco-friendly boats is also likely to drive expansion of the market, the report states.

Management Team

Alexandre Mongeon is Co-Founder and CEO of Vision Marine Technologies. He has served as CEO since 2014. Prior to that, he imported high-performance boats from the United States to Canada for more than 15 years. During much of that time, he also worked as a designer and contractor and managed several new construction projects on the waterfront in and around Montreal. He is a graduate of the School of Construction in Laval, Quebec, with a specialization in electrical systems.

Xavier Montagne is Chief Technical Officer at Vision Marine. Prior to joining the company, he was the CEO of Mac Engineering for six years. While there, he was the electric powerline architect of the Renault Trezor concept car (awarded 2016 Best Concept Car), technical designer of the Zoe E-sport race car driven in Formula-E races from 2016-2019 and senior battery designer for Forsee Power, SAFT, Renault and Peugeot in Europe, to mention a few of the many projects he headed. He received an electronic engineer diploma from IFITEP Paris Polytech in France.

Kulwant Sandher is CFO at Vision Marine. He is a Chartered Professional Accountant with more than 25 years of experience in business and finance. He has served as CFO of multiple public and private companies, including ElectraMeccanica Vehicles Corp., MineSense Technologies Inc., Alba Mineral Ltd., Delta Oil & Gas, Astorius Resources Ltd., Norsemont Mining Inc. and Intigold Mines Ltd. He graduated from Queen Mary College, University of London.

Vision Marine Technologies Inc. (NASDAQ: VMAR), closed Thursday's trading session at $0.79, off by 1.25%, on 42,642 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.69/$5.60.

Recent News

Clene Inc. (NASDAQ: CLNN)

The QualityStocks Daily Newsletter would like to spotlight Clene Inc. (NASDAQ: CLNN).

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company, and its wholly owned subsidiary Clene Nanomedicine Inc., is reporting on the full clinical results for CNM-Au8(R), an investigational first-in-class therapy designed to improve central nervous system cells' survival and function. Clene, which is focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis ("ALS") and multiple sclerosis ("MS"), presented the results at the ninth annual Americas Committee for Treatment and Research in Multiple Sclerosis Forum in Florida. The results were gathered from the VISIONARY-MS trial long-term open label extension ("LTE") in participants with stable relapsing multiple sclerosis ("RMS") totaling nearly three years of follow-up. According to the announcement, data gathered from the clinical trial indicate that long-term CNM-Au8 treatment results in "significant and clinically meaningful" improvement of vision and improvement of cognition. In addition, the company noted that treatment was well-tolerated, with no serious adverse events attributed to CNM-Au8 and no significant safety findings reported. The report noted that after completion of the double-blind period, 55 of 69 LTE-eligible study participants continued on CNM-Au8 30mg for up to an additional 96 weeks.

To view the full press release, visit https://ibn.fm/oVLIB

Clene Inc. (NASDAQ: CLNN) is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).

Its lead drug candidate is CNM-Au8®, an oral suspension developed to restore neuronal health and function by increasing energy production and utilization by driving critical cellular energy producing reactions that enable neuroprotection and remyelination to increase neuronal and glial resilience to disease-relevant stressors. CNM-Au8 is being studied in various clinical trials, including the Harvard/MGH Healey ALS Platform clinical trial for patients with ALS; RESCUE-ALS, a completed proof-of-concept clinical trial in patients with early symptomatic ALS; the REPAIR trials, completed target engagement clinical trials showing brain energy metabolite change with CNM-Au8; and a completed MS clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing MS. The company also has a nanotherapeutic platform of drug discovery.

CNM-Au8

CNM-Au8, Clene’s lead asset, is a highly concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals. Multiple pathogenic insults contribute to neuronal death. Mitochondrial dysfunction and NAD+ decline is a common final pathway in neurodegeneration, with NAD+ as a critical determinant of cell survival and function. CNM-Au8’s catalytic mechanisms target the energetic deficits, oxidative stress and accumulation of misfolded proteins that are common to many neurodegenerative diseases.

The unique catalytic mechanism of action of CNM-Au8 is hypothesized to act as a neuroprotective and remyelinating therapy in neurodegenerative disease states in order to: (1) drive, support and maintain beneficial metabolic and energetic cellular reactions within diseased, stressed and/or damaged cells, (2) directly catalyze the reduction of harmful, reactive oxygen species (“ROS”) and (3) promote protein homeostasis via activation of the heat shock factor-1 pathway, recognized to dampen the cytotoxicity caused by misfolded and denatured proteins, which are known to occur ubiquitously in neurodegenerative diseases.

CNM-Au8 is used in combination with other agents, has no known drug-drug interactions, and is designed to improve function and survival. The clinical effects of both function and survival were seen in its clinical ALS trials, as earlier announced.

More than 500 estimated years of collective exposure across ALS, MS, and Parkinson’s disease participants in CNM-Au8 clinical trials and Expanded Access Protocol (compassionate use) programs have been recorded without any observed safety signals.

CNM-Au8 is a federally registered trademark of Clene Inc. Clene, based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland, began in 2013.

Market Opportunity

ALS is the most prevalent adult-onset progressive motor neuron disease, affecting approximately 30,000 people in the U.S. and an estimated 500,000 people worldwide, with a life expectancy of typically three to five years. Clene estimates that global ALS treatment sales will be greater than $1 billion annually within the coming few years. Additional treatments affecting daily function and survival remain the market need.

Additionally, there are more than 2 million MS patients globally, and Clene estimates the market size to be worth more than $23 billion annually. While the MS community has been successful at limiting relapses, non-relapsing MS patients continue to clinically deteriorate even while receiving effective immunomodulatory disease-modifying therapies (“DMTs”). A critical unmet medical need remains for therapeutic interventions that protect neuronal function and myelin health independent of immunomodulation to address progression independent of relapse activity.

Management Team

Robert Etherington is President, Director and CEO of Clene. He has more than 30 years of sales, marketing and leadership experience in the pharmaceutical industry. Prior to joining Clene, he worked at Actelion Pharmaceuticals, the largest biopharma company in the European Union prior to its acquisition by Johnson & Johnson in 2017, where he led that company’s U.S. commercial operations. He began his pharmaceutical sales and marketing career at Parke-Davis, a division of Pfizer, where he rose to the position of Team Leader overseeing the drug Lipitor.

Mark Mortenson is Chief Science Officer at Clene. He is co-inventor of the technology platform developed to produce the company’s therapeutics. He is the inventor or co-inventor on 32 other U.S. patents and hundreds of corresponding international patents. He is a former chief patent counsel responsible for 5,500 U.S. and international patents and patent applications. He holds bachelor’s degrees in physics and ceramic engineering from Alfred University, a master’s degree in materials science from Penn State University and a J.D. from George Washington University.

Benjamin Greenberg, M.D., MHS, FAAN, is Head of Medical at Clene. He is an internationally recognized expert in disorders of the central nervous system. He is currently professor of neurology and Vice Chair of Clinical and Translational Research in the department of Neurology at University of Texas Southwestern Medical Center in Dallas. He holds a bachelor’s degree from Johns Hopkins, a master’s degree in molecular microbiology and immunology from the Johns Hopkins School of Public Health and graduated from Baylor College of Medicine. He served residency in neurology at The Johns Hopkins Hospital.

Morgan R. Brown is CFO at Clene. He has more than 30 years of finance and accounting experience, with 23 years at biotech, pharmaceutical and medical device companies. He has served in similar roles at Lipocine Inc., Innovus Pharmaceuticals, World Heart Corp., Lifetree Clinical Research and NPS Pharmaceuticals Inc. He previously worked at accounting firm KPMG. He is a CPA with a bachelor’s degree in accounting from Utah State University and an M.S. in business administration from the University of Utah.

Clene Inc. (NASDAQ: CLNN), closed Thursday's trading session at $0.4024, off by 7.2811%, on 1,750,160 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.25/$1.44.

Recent News

Sekur Private Data Ltd. (CSE: SKUR) (OTCQB: SWISF) (FRA: GDT0)

The QualityStocks Daily Newsletter would like to spotlight Sekur Private Data Ltd. (CSE: SKUR) (OTCQB: SWISF) (FRA: GDT0).

Sekur launched new solutions to benefit small to mid-sized businesses in the United States due to increased cyberattacks and business email compromise ("BEC") attacks during the presidential election year

Sekur SMB Privacy and Security solutions are equipped with countermeasures against BEC, including privacy communications solutions

Sekur also released SekurRelay as part of its Sekur Enterprise solution, addressing a common hurdle for large corporations and government agencies in adopting SekurMail

Sekur Private Data (CSE: SKUR) (OTCQB: SWISF) (FRA: GDT0), a cybersecurity and internet privacy provider of Swiss-hosted solutions for secure and private communications, recently announced the launch of new solutions to benefit small to mid-sized businesses in the United States due to the increase of cyberattacks and business email compromise ("BEC") attacks during the presidential election year. Sekur SMB Privacy and Security solutions are equipped with countermeasures against BEC, including privacy communications solutions (https://ibn.fm/bfDMD).

Sekur Private Data Ltd. (CSE: SKUR) (OTCQB: SWISF) (FRA: GDT0) is a Cybersecurity and Internet privacy provider of Swiss hosted solutions for secure and private communications. The company distributes a suite of encrypted e-mails, secure messengers and secure communication tools. Sekur Private Data Ltd. sells its products through its own website at www.Sekur.com, approved distributors, and telecommunications companies. Sekur Private Data Ltd. serves consumers, businesses and governments worldwide.

Customer information is completely confidential and safely stored in Switzerland using military grade security. All data, whether physical, network-based or encryption security, is stored in bank-approved, state-of-the-art ISO-certified data centers used by Swiss and global banks and most United Nations organizations, as well as many corporations and governmental organizations. All user data is protected by the Swiss Federal Data Protection Act and the Swiss Federal Data Protection Ordinance, which offer some of the strongest privacy protection in the world for both individuals and organizations.

The company owns 100% of its own infrastructure and, unlike its competitors, does not rely on third party cloud services like Amazon Web Services, Microsoft Azure Cloud or Google cloud infrastructure.

Sekur Private Data has chosen Switzerland to locate its data storage because of the country’s neutrality, independence, strong privacy laws, long standing political stability and excellent international relations. Switzerland is also home to several large multinational corporations and is ranked as having one of the strongest and most competitive economies in the world.

The company is headquartered in Toronto, Ontario.

Products

Sekur Private Data distributes a privacy communications suite offering encrypted and private email, the only Swiss-hosted privacy VPN, and a secure and private messaging application. All solutions cater to consumers, SMBs, enterprises and governments.

  • SekurMail® is an encrypted email service offering a private, safe and powerful tool to communicate with everyone, either within the Sekur ecosystem or outside. SekurMail protects personal information and communications from being accessed by unauthorized parties. Its encryption and other security measures prevent messages from being intercepted, modified or tampered with, either in transit or while stored. SekurMail empowers the client to access information and communicate with anyone in the world, regardless of geographical or political barriers.
  • SekurVPN® creates a secure, encrypted connection between the client’s device and the Internet, giving clients access to the web safely and privately by routing their connections through a server and hiding their online actions. All the data sent and received is hidden from prying eyes. This includes the clients’ Internet Service Providers, as well as potential hackers and even government surveillance agencies. It can also help clients bypass geographical restrictions and censorship.
  • SekurMessenger® is a Swiss-hosted private and secure messaging communications app providing secure and private chat, self-deleting chat, voice recording and file transfer via any mobile device, tablet or desktop computer. Communications are transmitted only within secure servers. It’s designed for organizations that need to protect their flow of information and secure their communications with customers and partners. SekurMessenger is designed to provide military-grade encryption and privacy by ensuring that only the sender and intended recipient can read the messages exchanged. It works for both licensed users of the app and intended message recipients who do not have the app.

Market Opportunity

An analysis from ReportLinker forecasts that the global cybersecurity market will grow from an estimated $173.5 billion in 2022 to $266.2 billion by 2027, recording a CAGR of 8.9% for the period.

The increased number of data breaches worldwide, the ability of malicious actors to operate from anywhere in the world, the links between cyberspace and physical systems and the difficulty of reducing vulnerabilities and consequences in complex cyber networks are some factors that are driving cybersecurity market growth, according to the report.

The global data privacy software market was estimated to be worth $1.68 billion in 2021 and is expected to grow from $2.36 billion in 2022 to $25.85 billion by 2029, achieving an eye-popping 40.8% CAGR during the forecast period, according to a Fortune Business Insights report titled ‘Data Privacy Software Market 2022-2029’.

The widespread shift toward remote working culture, evolving government data privacy regulations and the rapidly increasing adoption of Internet-of-Things devices are among the major factors propelling market growth, per the report.

Management Team

Alain Ghiai is founder, CEO and Director at Sekur Private Data. He also founded GlobeX Data S.A. (GDSA) in 2007 and has served as Director and CEO since then. He founded GlobeX Data Inc. (GlobeX US) in August 2012 and has served as Director and CEO since that time. He attended the California College of Arts in San Francisco, where he earned a Bachelor of Architecture. He has over 15 years of experience in the software industry and was instrumental in taking Sekur Private Data public in July 2019.

Scott Davis, CPA, CGA, is CFO at Sekur Private Data. He is also a partner at Cross Davis & Company LLP Chartered Professional Accountants. His experience includes CFO positions at several companies listed on the TSX Venture Exchange. He spent four years at Appleby as an Assistant Financial Controller. Prior to that, he spent two years at Davison & Company Chartered Professional Accountants as Auditor, five years with Pacific Opportunity Capital as Accounting Manager and two years at Jacobson Soda and Hosak, Chartered Professional Accountants. He obtained his CPA, CGA in 2003.

Learn more about the company’s management team by visiting its corporate page.

Sekur Private Data Ltd. (OTCQB: SWISF), closed Thursday's trading session at $0.04, off by 20.1198%, on 49,341 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.0394/$0.1576.

Recent News

GolfLync Inc.

The QualityStocks Daily Newsletter would like to spotlight GolfLync Inc.

GolfLync, a pioneering social networking platform for golf lovers, is celebrating a significant milestone: the company announced that it has reached — and passed — 100,000 members across the United States. According to the company, this achievement represents the platform's ability to enhance the golfing experience and foster a robust, interconnected community of golf enthusiasts. Key to the success of the new platform is its innovative Virtual Golf Clubs(TM) ("VGCs"); currently there are more than 850 active clubs around the country. The clubs enable golfers to share experiences, organize tee times, host events and forge lasting connections. The company noted that its growth and success parallels strategies that other influential social media giants have utilized as they shaped the future of social networking and cultivated user engagement. Those companies include Facebook and Instagram (NASDAQ: META), Pinterest (NYSE: PINS), Match (NASDAQ: MTCH), LinkedIn Corp. (NYSE: LNKD) and Snap Inc. (Snapchat) (NYSE: SNAP). GolfLync is committed to redefine the sport of golf, providing a way for golfers to connect and engage with each other. "Surpassing 100,000 members is a milestone that fills us with immense pride," said GolfLync cofounder and CEO Noah DiPasquale in the press release. "It echoes the strong sense of community our platform has nurtured, where golfers of all skill levels come together to share their passion. Our VGCs are more than just groups; they are thriving communities where friendships flourish."

To view the full press release, visit https://ibn.fm/Ki12K

GolfLync Inc. matches golfers looking for a game through the company’s smartphone app, GolfLync. The company bills GolfLync as “the social network for golfers,” matching golf games and players similar to the way a dating app matches those looking for romance.

The app allows like-minded golfers to connect for a game simply by logging in. GolfLync helps golfers who are looking to grow their golf network find other players with similar interests and on course preferences. Whether you have recently moved to a new area and are looking for new golfing buddies, travel frequently and would like to play a round of golf while on the road, or just want to meet new golfers in your area, GolfLync is your answer. Spouses who enjoy golfing together can find other golfing couples to tee it up with. For a regular group that finds itself unexpectedly down a player, GolfLync can help find that last-minute addition to complete the foursome.

The company is based in Scottsdale, Arizona.

GolfLync App

GolfLync was created for golfers of all skill levels and preferences to connect with compatible players of similar skill. Golfers can find a tee time through GolfLync, join existing tee times and create new leagues. The app allows golfers to meet fellow players before committing to spend four hours on the course with them. GolfLync allows users to find new golf friends based on their preferences, such as walking or riding a cart, listening to music, friendly wagering, imbibing a favorite beverage at the 19th Hole and more. GolfLync is available for both Android and iOS as a free download.

Download on Apple App Store   Get it on Google Play

Market Opportunity

According to a report by Statista, a leading provider of market and consumer data, in 2022, the number of people participating in golf in the United States reached 25.6 million, with 15.5 million additional players participating in off-course activities like driving ranges. In 2020, over 502 million rounds of golf were played in the U.S. alone. The game, traditionally dominated by male players, is changing, with increased interest from women golfers driven by social media influencers around the game.

Lumen Sports puts the total number of golf courses in the U.S. at more than 16,700. According to Lumen, about 75% of those are public courses open to all golfers, with the rest considered private golf clubs that require a membership.

 

Management Team

Noah DiPasquale is a co-founder and CEO of GolfLync Inc., leading the marketing and operations of the platform. He is also the founder and CEO of Epic Golf Club, a premier national membership and private golf society which partners with hundreds of top tier private golf clubs allowing Epic members access to their courses and recently founded the Epic Foundation, a Scottsdale-based 501c3. He holds a B.S. in Business Administration, Management and Operations from the W.A. Franke College of Business at Northern Arizona University and an MBA in Marketing from the University of Phoenix.

Michael Quiel is a co-founder of GolfLync Inc. and the President of the organization. He leads the application development and research teams. Michael understands how to build successful companies. His deep knowledge of investment banking, finance and building successful business partnerships is unparalleled. He’s an expert at capital formation and growth hacking companies. He has raised over $250 million in capital and taken multiple companies public.

Recent News

chart

Lexaria Bioscience Corp. (NASDAQ: LEXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX).

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 21 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has also collaborated with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has been granted patent protection for specific delivery of nicotine, vitamins, NSAIDs, antiviral drugs, cannabinoids and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

  • Speeds up delivery – the effects of the product are felt by the subject in just minutes.
  • Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
  • Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
  • Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
  • Reduces drug administration cost – lower doses mean lower overall drug costs.
  • Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

  • Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
  • Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
  • Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
  • Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
  • Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
  • Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Thursday's trading session at $3.45, up 35.2941%, on 1,029,740 volume. The average volume for the last 3 months is 199,563 and the stock's 52-week low/high is $0.6488/$3.5953.

Recent News

Sharing Services Global Corporation (SHRG)

The QualityStocks Daily Newsletter would like to spotlight Sharing Services Global Corporation (SHRG).

Sharing Services Global Corporation (SHRG), formerly Sharing Services Inc., is a diversified company dedicated to maximizing shareholder value, operating through two primary subsidiaries: Elepreneurs Holdings, a direct-selling company, and Elevacity Holdings, a products company. Headquartered in Plano, Texas, SHRG markets and distributes Elevate-branded health and wellness products through an independent sales force of distributors called Elepreneurs.

Proprietary Products

SHRG’s current exclusive Elevate product offerings are marketed under the Elevacity brand, so named to signify the company’s commitment to elevating lives.

The Elevate health and wellness product line consists of nutraceutical products that SHRG refers to as D.O.S.E., which stands for dopamine, oxytocin, serotonin and endorphins – all of which are key hormones proven to promote happiness and well-being.

Elevacity brand products are carefully formulated, chosen and designed to support a single objective: elevate the happiness and well-being of the consumer.

Global Network of Elepreneurs

Elevacity products are shared and sold by a growing international network of home-based entrepreneurs, called Elepreneurs, operated by Elepreneurs Holdings. This SHRG subsidiary provides basic and advanced programs for both new and experienced entrepreneurs who are focusing on their direct-sales careers.

SHRG’s high-performing independent sales force follows the company’s Blue Ocean selling strategy, an approach that encourages individuals to seek new markets, lead, and to “stop competing and start creating.” The Blue Ocean strategy is based on the book, “Blue Ocean Strategy,” written by Professor Renée Mauborgne, who notes that “the lesson here is that the best defense is offense, and the best offense… is to make a blue ocean shift and create your own blue ocean.”

Following this selling strategy, SHRG’s Elepreneurs are taught that, rather than competing directly in a competitive, direct-selling market, they should focus on making competitors irrelevant and succeeding in an uncontested marketplace.

In addition, SHRG’s Elepreneurs use the interactive, video-based VERB sales-marketing platform developed by Verb Technology Company Inc. The app utilizes proprietary interactive video data collection and analysis technology and provides next-generation customer relationship management, lead generation, and video marketing software applications.

Continued Momentum as Industry Leader

These selling strategies have resulted in sharp and consistent revenue gains. In the company’s 10-Q filed with the SEC for the three months ended Oct. 31, 2019, SHRG reported sales of $38.8 million for fiscal Q2 2019, an increase of 116% over sales of $17.9 million reported for the comparable quarter of 2018. Consolidated gross profit jumped by $16.2 million to $27.4 million for the same period compared to Q2 2018.

SHRG’s consolidated operating earnings were $3.9 million in the fiscal quarter ended Oct. 31, 2019, compared to $866,802 for the comparable period the prior year. Consolidated gross margin also grew 70.9% for the three months ended Oct. 31, 2019, compared to 62.2% the prior year.

These numbers are continuing a trend established over the past two years. In fiscal Q1 2019, SHRG achieved revenues of $35.4 million, more than double that of the comparable period in 2018. Even earlier, the company reported sales of $85.9 million for fiscal year ended April 30, 2019. This represents a nine-fold increase, or $77.5 million jump, over the company’s revenues of $8.4 million the prior year.

These numbers bring SHRG’s sales revenues since December 2017 — when the company’s Elevate product line was released — to an impressive cumulative total of $169 million.

Preparing for Success

SHRG is well prepared to continue and accommodate for this growth. The company recently expanded its corporate footprint by moving to a 10,000-square-foot facility in Plano, Texas, that offers ample room to expand as the company grows and flourish. The larger corporate locale provides space for a growing customer service department, product fulfillment, opportunity and training rooms, as well as a video production suite.

In addition, the company has a seasoned, expert leadership team in place, led by John “JT” Thatch. Thatch was appointed president and CEO of SHRG in March 2018, bringing to the company his expertise obtained from successfully starting, owning and operating several businesses in various industries. His experience with corporate growth, acquisitions, financing and negotiation in fast-paced and flexible environments will significantly assist SHRG as the company aims to expand and increase revenues.

Contact
469.304.9400 x 201
Info@SHRGinc.com
http://www.SHRGinc.com

Sharing Services Global Corporation (SHRG), closed the day's trading session at $1.01, up 23.17%, on 276,351 volume with 217 trades. The average volume for the last 3 months is 279,074 and the stock's 52-week low/high is $0.27/$2.54.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower
ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers

QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower
ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers

QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower
ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

370 N. Hayden Rd.
Suite 123-591
Scottsdale, AZ 85251
480-374-1336

Please read Disclaimers for FULL Compensation Disclosures and other disclaimers.

Copyright © .